Renin inhibition for hypertension: selecting the right role for a new class of drug.
Publication/Presentation Date
1-1-2010
Abstract
With the arrival of a new class of drugs for the management of hypertension comes the need to define its role. Aliskiren, an orally administered direct renin inhibitor, has been approved by the US Food and Drug Administration for the treatment of hypertension. Currently, the recommendation for choice of agent in the treatment of uncomplicated hypertension is a thiazide diuretic, and for patients with diabetic nephropathy, heart failure, or coronary artery disease, an angiotensin-converting enzyme inhibitor. Patients for whom an angiotensin-converting enzyme inhibitor is indicated who are intolerant as a result of side effects should take an angiotensin receptor blocker. A new class of medicines that specifically inhibits renin is an exciting addition to the armamentarium in the treatment of hypertension. This article explores the role of aliskiren in treating hypertension as well as its side effects and appropriate dosing.
Volume
17
Issue
2
First Page
182
Last Page
187
ISSN
1536-3686
Published In/Presented At
Bergset, J., Storozynsky, E., & Bisognano, J. D. (2010). Renin inhibition for hypertension: selecting the right role for a new class of drug. American journal of therapeutics, 17(2), 182–187. https://doi.org/10.1097/MJT.0b013e31819e9e9a
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
19433972
Department(s)
Administration and Leadership
Document Type
Article